Posted by Michael Wonder on 06 May 2025
Alterity Therapeutics granted US FDA fast track designation for ATH434 to treat multiple system atrophy
5 May 2025 - Alterity Therapeutics today announced that the US FDA has granted fast track designation for ATH434 for the treatment of multiple system atrophy.
Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.
